Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Frank J. Giles"'
Autor:
Taylor Weiskittel, Joseph McDermott, Daniel Billadeau, Hu Li, Anwaar Saeed, Devalingam Mahalingam, Solmaz Sahebjam, Pamela Munster, Ludimila Cavalcante, Frank J. Giles, Andrew Mazar, Benedito Carneiro
Publikováno v:
Cancer Research. 83:CT222-CT222
9-ING-41 (elraglusib) is a potent and selective GSK-3 inhibitor that has shown anti-tumor activity in patient-derived xenograft models and phase1/2 clinical studies in patients (pts) with advanced solid tumors. Preclinical studies have demonstrated t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::482a351ac875cfd407e70f68b2fd0a84
https://doi.org/10.1158/1538-7445.am2023-ct222
https://doi.org/10.1158/1538-7445.am2023-ct222
Autor:
June M, McKoy, Frank J, Giles
Publikováno v:
Cancer treatment and research. 171
An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosimilars with different approaches within major regu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0d8e8c3366e36d671d4812be7aedacf8
https://pubmed.ncbi.nlm.nih.gov/30552657
https://pubmed.ncbi.nlm.nih.gov/30552657
Autor:
Frank J. Giles, Andrew Jewell, C. P. Worman, Anthony H. Goldstone, Seah H. Lim, C. P. Tsakona
Publikováno v:
Cancer Immunology Immunotherapy. 33:133-137
In this study we investigated the pattern of T lymphocyte changes in 16 adult patients with acute myeloid leukaemia (8), non-Hodgkin's lymphoma (4) and Hodgkin's disease (4) treated with continuous infusion of recombinant interleukin-2 (rIL-2). Effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f610832a86fc1fad2808e5e9f755467
https://doi.org/10.1007/bf01742542
https://doi.org/10.1007/bf01742542
Autor:
Howard Ozer, Frank J. Giles
Publikováno v:
Current opinion in biotechnology. 2(6)
Recent studies have generated data demonstrating significant clinical activity of alpha-interferon therapy in each of six hematological malignancies, chronic myeloid leukaemia, essential thrombocythemia, polycythemia rubra vera, non-Hodgkin's lymphom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25732319389c80bdf052e2c6a1e1a6a7
https://pubmed.ncbi.nlm.nih.gov/1367959
https://pubmed.ncbi.nlm.nih.gov/1367959
Publikováno v:
British Journal of Haematology. 78:590a-591
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::063f7e8975cad582f1decb0dc4d09072
https://doi.org/10.1111/j.1365-2141.1991.tb04508.x
https://doi.org/10.1111/j.1365-2141.1991.tb04508.x